Nanocan Therapeutics

Nanocan Therapeutics Corporation is an early-stage biotechnology company dedicated to developing cutting-edge innovative therapeutic drugs based on nanotechnology to treat certain cancers and respiratory diseases that are currently underserved by existing interventions. Through collaborations with leading academic research institutions, Nanocan is rapidly advancing therapies that could ultimately establish new standards of care to help improve the lives of cancer patients. Nanocan is committed to delivering its disruptive innovations to cancer patients in low- and middle-income countries ("LMICs"), starting with African nations. Nanocan is simultaneously pursuing clinical trials and regulatory approvals in the United States and certain African countries.